Back to search

Article

Multimodal profiling for prediction of primary resistance to anti–PD-(L)1 therapy in advanced non-small-cell lung cancer: the prospective PIONeeR biomarkers study

2026-01-11

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Background</h4> Pretreatment prediction of primary resistance to anti–PD-(L)1 therapy in advanced non-small-cell lung cancer (NSCLC) remains an unmet clinical need. Existing biomarkers — including PD-L1 expression and tumour mutational burden (TMB) — are insufficiently discriminatory, and multimodal predictive models targeting primary resistance are still lacking to precisely drive patients...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
e47d8833-33b3-5c6b-a4d6-a10f40829f84
DOI
10.64898/2026.01.09.26343779
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Multimodal profiling for prediction of primary resistance to anti–PD-(L)1 therapy in advanced non-small-cell lung cancer: the prospective PIONeeR biomarkers studyDOI 10.64898/2026.01.09.26343779
A novel decision-making tool for first-line treatment selection in metastatic non-small cell lung cancer based on plasma proteome profilingSemantic proximity
Optimal treatment strategies for EGFR mutant advanced lung adenocarcinoma patients with targeted therapy resistance and correlation analysis of PD-L1 expression with ICI efficacy.Semantic proximity
Optimal Treatment Strategies for EGFR Mutant Advanced Lung Adenocarcinoma Patients with Targeted Therapy Resistance and Correlation Analysis of PD-L1 Expression with ICI EfficacySemantic proximity
Progression phenotypes to anti-PD-(L)1 therapy and subsequent management of patients with metastatic NSCLC: A real-world cohort study.Semantic proximity
High-dimensional immune profiling of peripheral blood identifies immune correlates of anti-PD-1/PD-L1 resistance in oncogenic driver mutation-positive NSCLC.Semantic proximity
From Variant to Biomarker in NSCLC Immunotherapy Resistance: Multiomics Evidence Chains and Accountable AI Integration.Semantic proximity
Tailoring Therapeutic Strategies in Non-Small-Cell Lung Cancer: The Role of Genetic Mutations and Programmed Death Ligand-1 Expression in Survival OutcomesSemantic proximity
Blood-based Genomic and Cellular Determinants of Response to Neoadjuvant PD-1 Blockade in Patients with Non-Small-Cell Lung CancerSemantic proximity
First-line treatment patterns and real-world outcomes in patients with advanced KRAS-mutated non-small cell lung cancer with high unmet need.Semantic proximity
Robust prediction of patient outcomes with immune checkpoint blockade therapy for cancer using common clinical, pathologic, and genomic featuresSemantic proximity
Antithetical impacts of deleterious LRP1B mutations in non-squamous and squamous NSCLCs on predicting benefits from immune checkpoint inhibitor alone or with chemotherapy over chemotherapy alone: retrospective analyses of the POPLAR/OAK and CHOICE-01 trials.Semantic proximity
Predictive value of the biomarker of peripheral blood of NSCLC patients responding to anti-PD-1 treatmentSemantic proximity
Select a neighboring publication to make it the new centre.